Market revenue in 2023 | USD 88.8 million |
Market revenue in 2030 | USD 132.8 million |
Growth rate | 5.9% (CAGR from 2023 to 2030) |
Largest segment | Crohn's disease |
Fastest growing segment | Ulcerative Colitis |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Crohn's Disease, Ulcerative Colitis |
Key market players worldwide | AbbVie Inc, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Biogen Inc, Novartis AG ADR, Eli Lilly and Co, UCB SA, Merck & Co Inc, Johnson & Johnson, Celltrion Healthcare |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to inflammatory bowel disease treatment market will help companies and investors design strategic landscapes.
Crohn's disease was the largest segment with a revenue share of 55.74% in 2023. Horizon Databook has segmented the Argentina inflammatory bowel disease treatment market based on crohn's disease, ulcerative colitis covering the revenue growth of each sub-segment from 2018 to 2030.
The drug Mesalamine shows the highest usage rate in the country, with 97% of the patients with UC and 32% of the patients with CD treated with the drug. This creates a major opportunity for mesalamine providers in Argentina. The introduction of biologics and biosimilars to treat IBD in the country is expected to fuel the market.
According to a Gastroenterology Research and Practice article published by Hindawi, the use of oral amino salicylates is high, followed by thiopurine and biologics, such as adalimumab, golimumab, infliximab, & vedolizumab, for treatment of ulcerative colitis & Crohn’s disease in Argentina.
Medications majorly focus on improvement of the immune system and halting inflammation in IBD patients. Furthermore, the presence of products developed by key players, such as Takeda Pharmaceuticals Ltd.; Pfizer, Inc.; and Johnson & Johnson Services, Inc., is expected to boost the market.
Horizon Databook provides a detailed overview of country-level data and insights on the Argentina inflammatory bowel disease treatment market , including forecasts for subscribers. This country databook contains high-level insights into Argentina inflammatory bowel disease treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account